Evidence map›Paper›PMID 22851716›Full record

ArticleMolecular pharmacology2012

P6981, an arylstibonic acid, is a novel low nanomolar inhibitor of cAMP response element-binding protein binding to DNA.

Jianfei Zhao, Jason R Stagno, Lyuba Varticovski, Eric Nimako, Vikas Rishi, Kathy McKinnon, Rhone Akee, Robert H Shoemaker, Xinhua Ji, Charles Vinson

Open access · bronzeAbstract read
In one paragraph

Article in Molecular pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. cAMP response element-binding protein: A credible cancer drug target.The Journal of pharmacology and experimental therapeutics · 2025
    Review
  3. Review
  4. Review
  5. What turns CREB on? And off? And why does it matter?Cellular and molecular life sciences : CMLS · 2020
    Review
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jianfei ZhaoLaboratory of Metabolism, National Cancer Institute, Bethesda, Maryland 20892, USA.
Jason R Stagno
Lyuba Varticovski
Eric Nimako
Vikas Rishi
Kathy McKinnon
Rhone Akee
Robert H Shoemaker
Xinhua Ji
Charles Vinson
Frederick National Laboratory for Cancer Research · USNational Cancer Institute · USScience Applications International Corporation (United States) · US

Funding

Biomolecular Structure and Mechanism, Structure-Based Drug DesignZIABC010326 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI JI, XINHUA · 2009 to 2024
$27.3M
Gene Regulation and Function: The B-ZIP ProteinsZIABC005271 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI VINSON, CHARLES · 2009 to 2019
$11.2M
CCR VB FACS COREZICBC010936 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MCKINNON, KATHERINE · 2009 to 2025
$10.9M
Intramural NIH HHS
6 · The paper itself

Abstract

Several basic leucine zipper (B-ZIP) transcription factors have been implicated in cancer, substance abuse, and other pathological conditions. We previously identified arylstibonic acids that bind to B-ZIP proteins and inhibit their interaction with DNA. In this study, we used electrophoretic mobility shift assay to analyze 46 arylstibonic acids for their activity to disrupt the DNA binding of three B-ZIP [CCAAT/enhancer-binding protein α, cyclic AMP-response element-binding protein (CREB), and vitellogenin gene-binding protein (VBP)] and two basic helix-loop-helix leucine zipper (B-HLH-ZIP) [USF (upstream stimulating factor) and Mitf] proteins. Twenty-five arylstibonic acids showed activity at micromolar concentrations. The most active compound, P6981 [2-(3-stibonophenyl)malonic acid], had half-maximal inhibition at ~5 nM for CREB. Circular dichroism thermal denaturation studies indicated that P6981 binds both the B-ZIP domain and the leucine zipper. The crystal structure of an arylstibonic acid, NSC13778, bound to the VBP leucine zipper identified electrostatic interactions between both the stibonic and carboxylic acid groups of NSC13778 [(E)-3-(3-stibonophenyl)acrylic acid] and arginine side chains of VBP, which is also involved in interhelical salt bridges in the leucine zipper. P6981 induced GFP-B-ZIP chimeric proteins to partially localize to the cytoplasm, demonstrating that it is active in cells. P6981 inhibited the growth of a patient-derived clear cell sarcoma cell line whose oncogenic potential is driven by a chimeric protein EWS-ATF1 (Ewing's sarcoma protein-activating transcription factor 1), which contains the DNA binding domain of ATF1, a B-ZIP protein. NSC13778 inhibited the growth of xenografted clear cell sarcoma, and no toxicity was observed. These experiments suggest that antimony containing arylstibonic acids are promising leads for suppression of DNA binding activities of B-ZIP and B-HLH-ZIP transcription factors.

Indexed as

Acids, NoncarboxylicAnimalsAntimonyBasic-Leucine Zipper Transcription FactorsCCAAT-Enhancer-Binding Protein-alphaCell Cycle CheckpointsCell LineCell Line, TumorCell SurvivalCinnamatesCircular DichroismCrystallography, X-RayCyclic AMP Response Element-Binding ProteinDNADrug Screening Assays, AntitumorElectrophoretic Mobility Shift Assay2-(3-stibonophenyl)malonic acidAcids, NoncarboxylicAntimonyBasic-Leucine Zipper Transcription FactorsCCAAT-Enhancer-Binding Protein-alphaCinnamatesCyclic AMP Response Element-Binding ProteinDNANSC 13778Organometallic CompoundsVitellogenins

Identifiers

PMID22851716
PMCPMC3477234
OpenAlexW2141081445

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.